My watch list  

Galapagos Genomics

Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies. Onno van de Stolpe is the CEO of the company.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.


  • Edwards PJ., The impact of parallel chemistry in drug discovery, IDrugs. 2006 May;9(5):347-53.

See also


  • Galapagos Genomics gaat zelf medicijnen ontwikkelen (Dutch)
  • Een rotsvast geloof in de Vlaamse biotech
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Galapagos_Genomics". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE